

# Nicolaus Andratschke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8927328/publications.pdf>

Version: 2024-02-01

133  
papers

4,164  
citations

117625

34  
h-index

138484

58  
g-index

139  
all docs

139  
docs citations

139  
times ranked

4374  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy for glioblastoma patients with poor performance status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2127-2136.	2.5	2
2	Single-isocenter versus multiple-isocenters for multiple lung metastases: Evaluation of lung dose. <i>Radiotherapy and Oncology</i> , 2022, 166, 189-194.	0.6	10
3	Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study. <i>Radiotherapy and Oncology</i> , 2022, 168, 256-264.	0.6	20
4	Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 170, 205-212.	0.6	17
5	Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 107-111.	1.7	2
6	Postoperative radiotherapy for meningiomas – a decision-making analysis. <i>BMC Cancer</i> , 2022, 22, 492.	2.6	1
7	Comprehensive summary and retrospective evaluation of prognostic scores for patients with newly diagnosed brain metastases treated with upfront radiosurgery in a modern patient collective. <i>Radiotherapy and Oncology</i> , 2022, 172, 23-31.	0.6	7
8	ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 197-206.	0.6	28
9	Prospective assessment of stress and health concerns of radiation oncology staff during the COVID-19 pandemic. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 110-117.	1.7	1
10	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.6	11
11	Development of staffing, workload and infrastructure in member departments of the European Organisation for Research and Treatment of Cancer (EORTC) radiation oncology group. <i>Radiotherapy and Oncology</i> , 2021, 155, 226-231.	0.6	12
12	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
13	In Regard to Ohri et Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 249-250.	0.8	1
14	Comparison of beam segment versus full plan re-optimization in daily magnetic resonance imaging-guided online-adaptive radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 43-46.	2.9	7
15	Management of multiple brain metastases: a patterns of care survey within the German Society for Radiation Oncology. <i>Journal of Neuro-Oncology</i> , 2021, 152, 395-404.	2.9	10
16	In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). <i>Scientific Reports</i> , 2021, 11, 4590.	3.3	6
17	High-dose re-irradiation of intracranial lesions – Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose calculation. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 132-138.	1.7	7
18	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 636672.	2.8	15

#	ARTICLE	IF	CITATIONS
19	Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis. <i>Cancers</i> , 2021, 13, 1840.	3.7	3
20	Head and neck radiotherapy on the MR linac: a multicenter planning challenge amongst MRIdian platform users. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1093-1103.	2.0	17
21	Current status and recent advances in resection cavity irradiation of brain metastases. <i>Radiation Oncology</i> , 2021, 16, 73.	2.7	27
22	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11566-11566.	1.6	5
23	Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. <i>Radiation Oncology</i> , 2021, 16, 84.	2.7	29
24	Distance to isocenter is not associated with an increased risk for local failure in LINAC-based single-isocenter SRS or SRT for multiple brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 159, 168-175.	0.6	22
25	Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. <i>Neuro-Oncology</i> , 2021, 23, 1612-1613.	1.2	1
26	Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. <i>Radiotherapy and Oncology</i> , 2021, 159, 106-111.	0.6	21
27	Long-Term Results of Dose-Intensified Fractionated Stereotactic Body Radiation Therapy (SBRT) for Painful Spinal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 348-357.	0.8	15
28	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 159, 146-154.	0.6	37
29	Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENTricular Tachycardia (RAVENTA) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 745-756.	0.8	28
30	Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. <i>Heart Rhythm</i> , 2021, 18, 2137-2145.	0.7	25
31	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	2.6	9
32	Stereotactic radioablation of ventricular arrhythmias in patients with structural heart disease – A systematic review. <i>Radiotherapy and Oncology</i> , 2021, 162, 132-139.	0.6	22
33	Margin calculation for multiple lung metastases treated with single-isocenter SBRT. <i>Radiotherapy and Oncology</i> , 2021, 162, 105-111.	0.6	4
34	Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 26-30.	1.7	3
35	True abscopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	2.7	8
36	MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. <i>Cancers</i> , 2021, 13, 5404.	3.7	13

#	ARTICLE	IF	CITATIONS
37	Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience. <i>Radiation Oncology</i> , 2021, 16, 217.	2.7	13
38	Estimation of the $\hat{I}\pm/\hat{I}^2$ ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 210-216.	0.6	22
39	Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. <i>European Journal of Cancer</i> , 2020, 124, 194-203.	2.8	13
40	Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. <i>Radiotherapy and Oncology</i> , 2020, 142, 217-223.	0.6	29
41	$^{18}\text{F}$ -FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non-“Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 113-117.	1.3	17
42	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020, 5, e000763.	4.5	20
43	Re-irradiation in the thorax “An analysis of efficacy and safety based on accumulated EQD2 doses. <i>Radiotherapy and Oncology</i> , 2020, 152, 56-62.	0.6	19
44	Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy: Long-Term Follow-Up Warranted. <i>Journal of Clinical Oncology</i> , 2020, 38, 3454-3455.	1.6	4
45	Treatment plan quality during online adaptive re-planning. <i>Radiation Oncology</i> , 2020, 15, 203.	2.7	36
46	Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 109-112.	2.9	13
47	Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. <i>Radiotherapy and Oncology</i> , 2020, 150, 30-39.	0.6	53
48	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
49	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. <i>JAMA Oncology</i> , 2020, 6, 1028.	7.1	122
50	A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. <i>Radiotherapy and Oncology</i> , 2020, 150, 1-3.	0.6	26
51	Generalizability assessment of head and neck cancer NTCP models based on the TRIPOD criteria. <i>Radiotherapy and Oncology</i> , 2020, 146, 143-150.	0.6	21
52	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. <i>Clinical and Translational Oncology</i> , 2020, 22, 1698-1709.	2.4	9
53	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 579-586.	0.8	40
54	Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 108.	2.4	23

#	ARTICLE	IF	CITATIONS
55	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. <i>Radiotherapy and Oncology</i> , 2020, 152, 203-207.	0.6	59
56	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2532-2532.	1.6	0
57	Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 104-112.	1.7	30
58	LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. <i>Acta Oncologica</i> , 2019, 58, 1275-1282.	1.8	50
59	Dosimetric comparison of protons vs photons in re-irradiation of intracranial meningioma. <i>British Journal of Radiology</i> , 2019, 92, 20190113.	2.2	6
60	Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial. <i>Annals of Oncology</i> , 2019, 30, v591.	1.2	7
61	MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. <i>Neuro-Oncology Advances</i> , 2019, 1, i17-i17.	0.7	0
62	MLTI-19. VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH BRAIN METASTASES: THE PICOS SCORE. <i>Neuro-Oncology Advances</i> , 2019, 1, i18-i18.	0.7	0
63	Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 961.	2.8	12
64	MLTI-09. UNDERWEIGHT AND WEIGHT LOSS ARE PREDICTORS OF POOR OUTCOME IN PATIENTS WITH BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , 2019, 1, i16-i16.	0.7	0
65	SP-0695 Systemic treatment as alternative or addition to radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S360.	0.6	0
66	Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2019, 80, 101892.	7.7	45
67	A Multi-Institutional Estimation of Interobserver Variability in Glioblastoma Delineation in the EORTC-1709-BTG /CCTG CE.8 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E617-E618.	0.8	1
68	Leukoencephalopathy after Prophylactic Whole-Brain Irradiation with or without Hippocampal Sparing: A Long-Term MRI Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E79.	0.8	0
69	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 339-347.	2.9	7
70	Interchangeability of radiomic features between [18F]â€‹scp>FDG PET</scp>/<scp>CT</scp> and [18F]â€‹scp>FDG PET</scp>/<scp>MR</scp>. <i>Medical Physics</i> , 2019, 46, 1677-1685.	3.0	22
71	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer – The ETOP NICOLAS trial. <i>Lung Cancer</i> , 2019, 133, 83-87.	2.0	113
72	The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. <i>BMC Cancer</i> , 2019, 19, 173.	2.6	68

#	ARTICLE	IF	CITATIONS
73	Stereotactic Radiosurgery for Multiple Brain Metastases. Current Treatment Options in Neurology, 2019, 21, 6.	1.8	38
74	How we treat patients with leptomeningeal metastases. ESMO Open, 2019, 4, e000507.	4.5	79
75	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 129, 63-71.	2.0	25
76	Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results. Radiotherapy and Oncology, 2019, 132, 63-69.	0.6	13
77	ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. Strahlentherapie Und Onkologie, 2019, 195, 193-198.	2.0	143
78	Pathologic Features of Tumor Activity and Stability in Uveal Melanoma Specimens after Fractionated CyberKnife Radiosurgery. Pathology and Oncology Research, 2019, 25, 731-740.	1.9	2
79	CT radiomics and PET radiomics: ready for clinical implementation?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 355-370.	0.7	58
80	Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. Cancer, 2018, 124, 2001-2009.	4.1	23
81	Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiotherapy and Oncology, 2018, 127, 246-252.	0.6	36
82	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. European Journal of Cancer, 2018, 96, 64-72.	2.8	17
83	Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Annals of Oncology, 2018, 29, 1431-1436.	1.2	73
84	Optimization of combined proton-photon treatments. Radiotherapy and Oncology, 2018, 128, 133-138.	0.6	26
85	Correspondence on Rajyaguru et al. Journal of Clinical Oncology, 2018, 36, 2561-2562.	1.6	2
86	Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity. Frontiers in Oncology, 2018, 8, 551.	2.8	32
87	The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer, 2018, 18, 283.	2.6	115
88	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. Journal of Clinical Oncology, 2018, 36, 8510-8510.	1.6	20
89	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. Journal of Clinical Oncology, 2018, 36, e14062-e14062.	1.6	0
90	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiotherapy and Oncology, 2017, 123, 182-188.	0.6	55

#	ARTICLE	IF	CITATIONS
91	Stereotactic body radiotherapy for oligo-metastatic liver disease – Influence of pre-treatment chemotherapy and histology on local tumor control. <i>Radiotherapy and Oncology</i> , 2017, 123, 227-233.	0.6	85
92	P2.05-044 Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1058-S1059.	1.1	0
93	Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 357-364.	0.6	15
94	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 11-17.	0.6	230
95	Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 511-520.	0.8	42
96	CMET-26. DIAGNOSTIC VALUE OF FDG-PET/CT FOR PATIENTS WITH BRAIN METASTASIS FROM UNKNOWN PRIMARY SITE. <i>Neuro-Oncology</i> , 2017, 19, vi44-vi44.	1.2	0
97	Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases – A pooled analysis of the German working group – stereotactic radiotherapy. <i>Lung Cancer</i> , 2016, 97, 51-58.	2.0	128
98	Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. <i>Radiation Oncology</i> , 2016, 11, 74.	2.7	28
99	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 841-849.	0.8	19
100	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 485-491.	0.6	101
101	Re-irradiation for Recurrent Primary Brain Tumors. <i>Anticancer Research</i> , 2016, 36, 4985-4996.	1.1	47
102	Long-Term Survival in Metastasized Leiomyosarcoma: A Case Report and Review of the Literature. <i>Tumori</i> , 2015, 101, e141-e144.	1.1	4
103	Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. <i>Radiation Oncology</i> , 2015, 10, 100.	2.7	104
104	Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib. <i>Radiation Oncology</i> , 2015, 10, 29.	2.7	11
105	Stereotactic body radiotherapy for centrally located stage I NSCLC. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 125-132.	2.0	52
106	Adhesion Molecule Expression and Function of Primary Endothelial Cells in Benign and Malignant Tissues Correlates with Proliferation. <i>PLoS ONE</i> , 2014, 9, e91808.	2.5	20
107	Development of a Score Predicting Survival after Palliative Reirradiation. <i>Journal of Oncology</i> , 2014, 2014, 1-7.	1.3	6
108	Support Vector Machine-Based Prediction of Local Tumor Control After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 732-738.	0.8	54

#	ARTICLE	IF	CITATIONS
109	SBRT in operable early stage lung cancer patients. <i>Translational Lung Cancer Research</i> , 2014, 3, 212-24.	2.8	7
110	Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 13-20.	0.6	103
111	Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1050-1058.	1.1	179
112	Adding cetuximab to stereotactic radiotherapy for non-small cell lung cancer might reduce local failure rates. <i>Medical Hypotheses</i> , 2012, 78, 420-422.	1.5	3
113	Stereotactic ablative radiotherapy for inoperable stage I NSCLC. <i>Lancet Oncology</i> , The, 2012, 13, 746-748.	10.7	2
114	Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. <i>Radiotherapy and Oncology</i> , 2011, 100, 160-166.	0.6	103
115	Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2011, 101, 245-249.	0.6	106
116	Late residual gamma-H2AX foci in murine spinal cord might facilitate development of response-modifying strategies: a research hypothesis. <i>Anticancer Research</i> , 2011, 31, 561-4.	1.1	3
117	Quality of Training in Radiation Oncology in Germany. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 239-244.	2.0	18
118	Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine. <i>Journal of Nuclear Medicine</i> , 2007, 48, 973-980.	5.0	92
119	Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 163-168.	0.8	23
120	Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. <i>Anticancer Research</i> , 2007, 27, 183-7.	1.1	0
121	Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. <i>Anticancer Research</i> , 2007, 27, 2353-7.	1.1	3
122	Current status of angiogenesis inhibitors combined with radiation therapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 348-364.	7.7	109
123	Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1513-1518.	0.8	12
124	Acceleration of Normal-Tissue Damage Expression by Early Stimulation of Cell Proliferation in Rat Spinal Cord. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 680-684.	2.0	6
125	Effects of Insulin-Like Growth Factor-1 (IGF-1) and Amifostine in Spinal Cord Reirradiation. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 691-695.	2.0	17
126	Evaluation of insulin-like growth factor-1 for prevention of radiation-induced spinal cord damage. <i>Growth Factors</i> , 2005, 23, 15-18.	1.7	9



#	ARTICLE	IF	CITATIONS
127	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Review of Neurotherapeutics, 2004, 4, 691-703.	2.8	18
128	Radiotherapy for High-Grade Gliomas. Strahlentherapie Und Onkologie, 2004, 180, 401-407.	2.0	90
129	Recursive Partitioning Analysis (RPA) Class Does Not Predict Survival in Patients with Four or More Brain Metastases. Strahlentherapie Und Onkologie, 2003, 179, 16-20.	2.0	51
130	The role of growth factors in central nervous system tumours. Anticancer Research, 2003, 23, 1681-6.	1.1	13
131	Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Research, 2003, 23, 5117-23.	1.1	20
132	Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Research, 2002, 22, 1017-23.	1.1	16
133	Predicting Adverse Radiation Effects in Brain Tumors After Stereotactic Radiotherapy With Deep Learning and Handcrafted Radiomics. Frontiers in Oncology, 0, 12, .	2.8	3